Compounding Pharmacy Market 2017: Industry Research, Review, Share, Trends, Growth, Segment, Analysis & Forecast to 2022

This report covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies

PUNE, INDIA, December 14, 2017 /EINPresswire.com/ — The report provides a comprehensive analysis of the Compounding Pharmacy industry market by types, applications, players and regions. This report also displays the production, Consumption, revenue, Gross margin, Cost, Gross, market share, CAGR, and Market influencing factors of the Compounding Pharmacy industry in USA, EU, China,India, Japan and other regions, and forecast to 2022, from 2017.

Market Analysis by Players
Fagron,
Wedgewood Pharma,
CAPS,
Fresenius Kabi,
PharMEDium Services,
Cantrell Drug,
Advanced Pharma,
Dougherty's Pharmacy,
Institutional Pharmacy Solutions,
Lorraine's Pharmacy,
Village Compounding Pharmacy,
Triangle Compounding Pharmacy
Olympia Pharmacy

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/1577101-2017-global-compounding-pharmacy-industry-research-report

Market Analysis by Regions:
USA
Europe
Japan
China
India
Southeast Asia
South America
South Africa
Others

Market Analysis by Types:
Pharmaceutical Ingredient Alteration (PIA)
Pharmaceutical Application Alteration (PAA)
Currently Unavailable Pharmaceutical Manufacturing (CUPM)
Pharmaceutical Dosage Alteration (PDA)
Specialized Animal Pharmaceutical Manufacturing (SAPM)

Market Analysis by Applications:
Children
Teens
Adults
The Elderly

Make an enquiry of this Report @ https://www.wiseguyreports.com/enquiry/1577101-2017-global-compounding-pharmacy-industry-research-report

Table of Content

1 Compounding Pharmacy Market Overview
1.1 Product Overview of Compounding Pharmacy
1.2 Classification and Application of Compounding Pharmacy
1.3 Global Compounding Pharmacy Market Regional Analysis
1.3.1 USA Market Present Situation Analysis
1.3.2 Europe Market Present Situation Analysis
1.3.3 Japan Market Present Situation Analysis
1.3.4 China Market Present Situation Analysis
1.3.5 India Market Present Situation Analysis
1.3.6 Southeast Asia Market Present Situation Analysis
1.3.7 South America Market Present Situation Analysis
1.3.8 South Africa Market Present Situation Analysis
1.4 Compounding Pharmacy Industry Development Factors Analysis
1.4.1 Compounding Pharmacy Industry Development Opportunities Analysis
1.4.2 Compounding Pharmacy Industry Development Challenges Analysis
1.5 Compounding Pharmacy Consumer Behavior Analysis

2 Global Compounding Pharmacy Competitions by Players
2.1 Global Compounding Pharmacy Sales (Unit) and Market Share (%) by Players
2.2 Global Compounding Pharmacy Revenue (Million USD) and Share by Players (2016-2017)
2.3 Global Compounding Pharmacy Price (USD/Unit) by Players (2016-2017)
2.4 Global Compounding Pharmacy Gross Margin by Players (2016-2017)

3 Global Compounding Pharmacy Competitions by Types
3.1 Global Compounding Pharmacy Sales (Unit) and Market Share (%) by Types
3.2 Global Compounding Pharmacy Revenue (Million USD) and Share by Type (2012-2017)
3.3 Global Compounding Pharmacy Price (USD/Unit) by Type (2012-2017)
3.4 Global Compounding Pharmacy Gross Margin by Type (2012-2017)
3.5 USA Compounding Pharmacy Sales (Unit) and Market Share (%) by Type
3.6 China Compounding Pharmacy Sales (Unit) and Market Share (%) by Type
3.7 Europe Compounding Pharmacy Sales (Unit) and Market Share (%) by Type
3.8 Japan Compounding Pharmacy Sales (Unit) and Market Share (%) by Type
3.9 India Compounding Pharmacy Sales (Unit) and Market Share (%) by Type
3.10 Southeast Asia Compounding Pharmacy Sales (Unit) and Market Share (%) by Type
3.11 South America Compounding Pharmacy Sales (Unit) and Market Share (%) by Type
3.12 South Africa Compounding Pharmacy Sales (Unit) and Market Share (%) by Type

4 Global Compounding Pharmacy Competitions by Application
4.1 Global Compounding Pharmacy Sales (Unit) and Market Share (%) by Application
4.2 Global Compounding Pharmacy Revenue (Million USD) and Share by Application (2012-2017)
4.3 Global Compounding Pharmacy Price (USD/Unit) by Application (2012-2017)
4.4 Global Compounding Pharmacy Gross Margin by Application (2012-2017)
4.5 USA Compounding Pharmacy Sales (Unit) and Market Share (%) by Application
4.6 China Compounding Pharmacy Sales (Unit) and Market Share (%) by Application
4.7 Europe Compounding Pharmacy Sales (Unit) and Market Share (%) by Application
4.8 Japan Compounding Pharmacy Sales (Unit) and Market Share (%) by Application
4.9 India Compounding Pharmacy Sales (Unit) and Market Share (%) by Application
4.10 Southeast Asia Compounding Pharmacy Sales (Unit) and Market Share (%) by Application
4.11 South America Compounding Pharmacy Sales (Unit) and Market Share (%) by Application
4.12 South Africa Compounding Pharmacy Sales (Unit) and Market Share (%) by Application

5 Global Compounding Pharmacy Production Market Analysis by Region
5.1 Global Compounding Pharmacy Production (Unit) and Market Share (%) by Region
5.1.1USA Compounding Pharmacy Market Production Present Situation Analysis
5.1.2 Europe Compounding Pharmacy Market Production Present Situation Analysis
5.1.3 China Compounding Pharmacy Market Production Present Situation Analysis
5.1.4 Japan Compounding Pharmacy Market Production Present Situation Analysis
5.1.5 India Compounding Pharmacy Market Production Present Situation Analysis
5.1.6 Southeast Asia Compounding Pharmacy Market Production Present Situation Analysis
5.1.7 South America Compounding Pharmacy Market Production Present Situation Analysis
5.1.8 South Africa Compounding Pharmacy Market Production Present Situation Analysis
5.2 Global Compounding Pharmacy Production Value (Million USD) and Share by Region (2012-2017)
5.3 Global Compounding Pharmacy Price (USD/Unit) by Region (2012-2017)
5.4 Global Compounding Pharmacy Gross Margin by Region (2012-2017)

6 Global Compounding Pharmacy Sales Market Analysis by Region
6.1 USA Compounding Pharmacy Market Consumption Present Situation Analysis
6.2 Europe Compounding Pharmacy Market Consumption Present Situation Analysis
6.3 China Compounding Pharmacy Market Consumption Present Situation Analysis
6.4 Japan Compounding Pharmacy Market Consumption Present Situation Analysis
6.5 India Compounding Pharmacy Market Consumption Present Situation Analysis
6.6 Southeast Asia Compounding Pharmacy Market Consumption Present Situation Analysis
6.7 South America Compounding Pharmacy Market Consumption Present Situation Analysis
6.8 South Africa Compounding Pharmacy Market Consumption Present Situation Analysis

7 Imports and Exports Market Analysis
7.1 USA Compounding Pharmacy Imports and Exports Analysis (2012-2017)
7.2 Europe Compounding Pharmacy Imports and Exports Analysis (2012-2017)
7.3 China Compounding Pharmacy Imports and Exports Analysis (2012-2017)
7.4 Japan Compounding Pharmacy Imports and Exports Analysis (2012-2017)
7.5 India Compounding Pharmacy Imports and Exports Analysis (2012-2017)
7.6 Southeast Asia Compounding Pharmacy Imports and Exports Analysis (2012-2017)
7.7 South America Compounding Pharmacy Imports and Exports Analysis (2012-2017)
7.8 South Africa Compounding Pharmacy Imports and Exports Analysis (2012-2017)

……Continued

Purchase Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1577101

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Increasing Incidence of Blindness are Expected to Impel the Growth of Diabetic Retinopathy Drug Market in Future,

Diabetic Retinopathy Drug Market

Diabetic Retinopathy Drug Market

Rising Number of Patient Suffering from Diabetics and Increasing Incidence of Blindness are Expected to Impel the Growth of Diabetic Retinopathy Drug Market

BROOKYLN, 11230, UNITED STATES, December 14, 2017 /EINPresswire.com/ — “Global Diabetic Retinopathy Drug Market Analysis & Opportunity Outlook 2021”

The global diabetic retinopathy drug market is segmented into type of drugs such as intraocular steroid injection, avastin, lucentis and anti-vascular endothelial growth factor (VEGF) drug. Among these segments, anti-vascular endothelial growth factor (VEGF) drug segment is expected witness considerable growth during the forecast period. The growth of the anti-vascular endothelial growth factor (VEGF) drug segment can be attributed to its beneficiary features such as better treatment and faster recovery. Additionally, increasing number of incidence of proliferative diseases is likely to bolster the growth of this segment over the forecast period.

Global diabetic retinopathy drug market is expected to flourish at a robust CAGR over the forecast period. Moreover, the global diabetic retinopathy drug market is expected to reach at notable revenue of around USD 705 Million by the end of 2021. The market is expected to expand on the back of increasing incidence of eye diseases across the globe. Furthermore, increasing number of patients suffering from diabetes is a major factor which is increasing the occurrence of diabetic retinopathy which in turn expected to fuel the demand for diabetic retinopathy drugs in near future.

The North America segment by region accounted for more than 35% market share of overall diabetic retinopathy drug market in 2015. This growth in North America can be attributed to increasing prevalence of diabetic retinopathy amongst the consumers aged 40 and older in United States.Furthermore, the occurrence rate of diabetic retinopathy for adults in North America is 28.5%.

Increasing Geriatric Population

The world’s geriatric population is continually growing at an unprecedented rate. Further, high occurrence of diabetes among older population of world is a major factor which is causing incidence of diabetic retinopathy diseases across the globe. Apart from this, the occurrence of diabetes is increasing in developed countries such as United States, Australia and others. Furthermore, increasing incidence of diabetic retinopathy diseases among geriatric population is a major factor which is likely to propel the demand for diabetic retinopathy drugs during the forecast period.

Request For Sample Pages: https://www.researchnester.com/sample-request/2/rep-id-99

Increasing Prevalence of Diabetes

Increasing number of patients having diabetes are at major risk of developing diabetic retinopathy diseases. Moreover, diabetes is one of the most common diseases in school aged children. Increasing prevalence of diabetes is a major factor which is causing diabetic retinopathy diseases across the globe which in turn likely to increase the consumption of diabetic retinopathy drugs over the forecast period.
Although, insufficient healthcare access, stringent government regulations for approval of diabetic retinopathy drugs and lack of skilled ophthalmologists are some of the factors that are likely to inhibit the growth of the diabetic retinopathy drug market in the near future.

The report titled “Global Diabetic Retinopathy Drug Market Analysis & Opportunity Outlook 2021” delivers detailed overview of the global diabetic retinopathy drug market in terms of market segmentation by type of drugs, by end-users and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Request For TOC Pages: https://www.researchnester.com/toc-request/1/rep-id-99

This report also provides the existing competitive scenario of some of the key players of the global diabetic retinopathy drug market which includes company profiling of F. Hoffmann-La Roche AG, Moore Drug Company, Regeneron Pharmaceuticals Inc., Bayer Healthcare, Novartis AG, ThromboGenics NV, Actavis PLC, Sirnaomics Incorporation, Gilead Science and Parexel International Corp. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global diabetic retinopathy drug market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Request For Pre- Book Now: https://www.researchnester.com/payment/rep-id-99

Ajay Daniel
Research Nester
+1 646 586 9123
email us here


Source: EIN Presswire

The Global Peptide Therapeutics Market is Anticipated to Mark A CAGR of 8.2% by 2023

Peptide Therapeutics Market

Peptide Therapeutics Market

The Global Peptide Therapeutics Market is Anticipated to Mark A CAGR of 8.2% by 2023, According to Research Nester

BROOKYLN, 11230, UNITED STATES, December 14, 2017 /EINPresswire.com/ —
The global peptide therapeutics market is segmented into application such as cancer, cardiovascular, central nervous system, metabolic disorders, infection, hematological disorders, gastrointestinal disorders, respiratory disorders and acromegaly. Among these segments, cancer segment is projected to be the fastest growing segment by 2024. Likely, rising demand for peptide therapeutics owing to growing occurrence of long term diseases such as cancer is predicted to propel the growth of global peptide therapeutics market. Moreover, rise in spending on healthcare is yet another major growth driving the growth of peptide therapeutics market.

Global peptide therapeutics market is projected to register a CAGR of 8.2% over the forecast period i.e. 2016-2023. Moreover, the global peptide therapeutics market is anticipated to reach at noteworthy revenue of USD 26.2 Billion by 2023. The market is expected to expand on the back of increasing investment in healthcare sector by the government authorities.

The parenteral segment by route of administration is projected to grab the biggest share in overall peptide therapeutics market by 2023. In the terms of geography, highest demand for peptide therapy was seen from North-America. Further, increasing aging population and favorable reimbursement policies are some of the factors propelling the growth of peptide therapeutics market. Apart from this, Asia-Pacific peptide therapeutics market is expected to expand at a robust CAGR during the forecast period owing to rapid expansion of biotech companies.

Increasing Geriatric Population

Increase in aging population across the globe is believed to trigger the prevalence of diseases such as cardiac, cardiovascular and osteoporosis which is likely to increase the burden on emerging economies, thus intensifying the demand for peptide therapeutics so as to reduce the burden and minimize the health expenditure.

Request For Free Sample Pages: https://www.researchnester.com/sample-request/2/rep-id-180

Rising Healthcare Expenditure

Rising biotech companies and increasing healthcare spending by the government authorities, rising prevalence of cancer and nervous system disorders are some of the factors expected to fuel the demand for peptide therapeutics in near future. Furthermore, rising awareness towards peptide therapeutics and introduction of favorable re-imbursement policies by the government organizations across the globe is envisioned to bolster the growth of the global peptide therapeutics market in next upcoming years.

Although, high cost of peptide therapeutics is expected to limit the growth of peptide therapeutics market by the end of 2023. Moreover, lack of awareness in under-developed nations is hindering the demand for peptide therapeutics.
The report titled “Peptide Therapeutics Market: Global Market Size, Demand Analysis & Opportunity Outlook 2023” delivers detailed overview of the global peptide therapeutics market in terms of market segmentation by application, by route of administration, by Synthesis, by drugs, by type of molecule, by end-user and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Request For TOC Pages: https://www.researchnester.com/toc-request/1/rep-id-180

This report also provides the existing competitive scenario of some of the key players of the global peptide therapeutics market which includes company profiling of Teva Pharmaceutical Ltd., Novartis AG, Bachem Holdings AG, Sanofi, Pfizer Inc., Novo Nordisk, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., F. Hoffmann-La Roche Ltd. and Takeda Pharmaceutical Industries Ltd. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global peptide therapeutics market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Request For Buy Now: https://www.researchnester.com/payment/rep-id-180

Ajay Daniel
Research Nester
+1 646 586 9123
email us here


Source: EIN Presswire

Pediatric is Likely to Drive the Growth of Pediatric Vaccines Market at a CAGR of 10.6% During the Forecast Period

Pediatric Vaccines Market

Pediatric Vaccines Market

Rising Awareness Regarding Pediatric Vaccines is Likely to Drive the Growth of Pediatric Vaccines Market at a CAGR of 10.6% During the Forecast Period

BROOKYLN, 11230, UNITED STATES, December 14, 2017 /EINPresswire.com/ —
The global pediatric vaccines market is segmented into product type such as synthetic vaccines, dendritic cells vaccines, toxoid vaccines, live attenuated vaccines, inactivated vaccines, subunit vaccines and recombinant vector vaccines. Among these segments, live attenuated vaccines segment is expected to witness significant growth during the forecast period. The rise of the live attenuated segment is backed by its excellent immune response and better outcome. Moreover, this vaccine technology is mainly used in Polio and hepatitis vaccination.

Global pediatric vaccines market is expected to register a CAGR of 10.6% over the forecast period. Moreover, the global pediatric vaccines market was valued at USD 24 Billion in 2015 and is expected to reach at notable revenue by the end of 2021. The market is expected to expand on the back of favorable government initiatives and increasing concerns amongst the population regarding child safety and health. Some common vaccines are recommended for children’s such as Hapatitis B, DIPHTHERIA, Poliomyelitis and others.

The hepatitis and poliomyelitis by diseases are likely to grow at satisfactory pace during the forecast period. Government initiatives and vaccinations programs to cover maximum population across the region and growing awareness among the population regarding essential vaccines are major factors which are anticipated to bolster the growth of pediatric vaccines market.

Escalating Number of Newborns

According to world health organization, more than 130 Million live births per year across the globe. Further, rising need to prevent infants from vaccine preventable diseases such as cervical cancer, polio, pneumonia, diphtheria, mumps and other is a key factor which is driving the growth of pediatric vaccines market. Moreover, increasing concern regarding child’s health and wellness coupled with increasing expenditure on care of newborns are also fuelling the demand for pediatric vaccines across the globe.

Request For Free Sample Pages: https://www.researchnester.com/sample-request/2/rep-id-120

Favourable government initiatives and programmes

The pediatric vaccines market is poised to display substantial growth during the forecast period due to favorable government initiatives and vaccination programs across the globe. Furthermore, number of deaths due to vaccine-preventable diseases such as rubella, measles, tetanus, rotavirus and other diseases are increasing. Government expenditures on improvement of healthcare sector and to provide better medical services are anticipated to bolster the growth of pediatric vaccine market during the forecast period.

However, low access to vaccines in remote areas, low healthcare spending and lower pediatric vaccination coverage are some of the factors that are likely to inhibit the growth of the pediatric vaccines market in the near future.
The report titled “Global Pediatric Vaccines Market Analysis & Opportunity Outlook 2021” delivers detailed overview of the global pediatric vaccines market in terms of market segmentation by types, by diseases and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Request For TOC Pages: https://www.researchnester.com/toc-request/1/rep-id-120

This report also provides the existing competitive scenario of some of the key players of the global pediatric vaccines market which includes company profiling of Pfizer Inc., Merck & Co., Inc., Sanofi Pasteur, Sinovac Biotech, Bio Med, Valeant Pharmaceuticals and Dynavax Technologies. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global pediatric vaccines market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Request For Buy Now: https://www.researchnester.com/payment/rep-id-120

Ajay Daniel
Research Nester
+1 646 586 9123
email us here


Source: EIN Presswire

Judge to scrutinize Enhanced Athlete’s harassment campaign against Tauler Smith LLP

Enhanced Athlete's partners, a convicted felon and a bankruptcy attorney, face sanctions at January hearing

Enhanced Athlete’s egregious, illegal, and vexatious harassment 'directly impacts the integrity of the judicial process … which justifies the imposition of sanctions.'”

— Attorney Robert Tauler

LOS ANGELES, CALIFORNIA, USA, December 13, 2017 /EINPresswire.com/ — Enhanced Athlete, a sports supplement company accused of touting a fertilizer used in explosives for human consumption as a weight loss drug, in January will have to persuade a judge to support its latest attempt to attack the plaintiff trying to stop the illegal practice.

One of Enhanced Athlete’s principals, convicted felon Scott Cavell recently called the lawsuit “frivolous” and accused the company and the lawyer seeking to put an end to the illegal sale and harmful use of DNP (dinitrophenol) of being engaged in a “shakedown” scheme.

Phoenix-based Nutrition Distribution LLC, through its lawyer Robert Tauler of Tauler Smith LLP, earlier this year sued Enhanced Athlete and Cavell, alleging false advertising, promotion and sales for human consumption of DNP. According to the Guardian newspaper, DNP is responsible for the deaths of more than 60 people since 2015.

In September Cavell, in an email to Enhanced Athlete’s followers, encouraged clients to threaten, harass and otherwise impede and interfere with Tauler Smith and Nutrition Distribution’s businesses. The email provided directions on what specific actions they could take, including crashing servers, sending disrupting emails, filling voicemails, and spreading parking lots with nails and other hazards – all illegal acts.

“We need as much information as you can discover, nothing is to (sic) small or insignificant to share. Girl friends (sic) or wive’s (sic) names, places of employment, phone numbers or addresses. Any contact information for anyone that works with the plaintif (sic) or attorney, ie cell phone numbers home addresses etc,” wrote Cavell. Cavell then offered a discount on merchandise if the harassment was effective in obtaining a voluntary dismissal of the DNP lawsuit and another one accusing the company of illegal sales and promotion of SARMs, a type of steroid.

In November Cavell issued a press release claiming it had won a significant courtroom victory when a judge denied Nutrition Distribution’s motion for preliminary injunction to enjoin Enhanced Athlete’s sale of DNP. Cavell and Enhanced Athlete again promised followers a half-off sale on all merchandise if Nutrition Distribution dismisses the lawsuits.

Enhanced Athlete’s harassment “directly impacts the integrity of the judicial process,” Tauler said in court papers seeking to sanction Cavell and Enhanced Athlete for their misconduct. “Defendants continuation of their harassment campaign against Plaintiff and its counsel for bringing claims against Defendants constitute egregious, illegal, and vexatious bad faith misconduct, which justifies the imposition of sanctions.”

Tauler filed the motion Nov. 11 in U.S. District Court in Sacramento, asking the judge to sanction Enhanced Athlete for its attempt to disrupt business and damage the reputations of Tauler Smith and Nutrition Distribution.

Robert Tauler
Tauler Smith LLP
310-590-3927
email us here


Source: EIN Presswire

NACCHO Releases Standards and Indicators for Hospital-based Injury and Violence Prevention Programs

Voluntary Standards Developed in Collaboration with the Safe States Alliance

WASHINGTON, DC, UNITED STATES, December 13, 2017 /EINPresswire.com/ — Unintentional injury is a leading cause of death for those between the ages of 1 and 44, and injuries account for approximately $671 billion in medical and work-loss costs. These injuries include but are not limited to child maltreatment, domestic and intimate partner violence, drowning, elder abuse, falls, firearm safety, motor vehicle safety, opioid abuse, poisonings, sexual assault and rape, suicide and self-inflicted injuries, traumatic brain injury and youth violence.

The National Association of County and City Health Officials (NACCHO), representing nearly 3,000 local governmental health departments, has developed voluntary standards of injury and violence prevention (IVP) programs in collaboration with the Safe States Alliance. The Safe States Alliance’s mission is to strengthen the practice of injury and violence prevention.

These new standards are the first step towards providing guidance on the design and implementation of a model IVP program for Level I and Level II trauma center IVP programs. They are designed to support the IVP professional and hospital leadership with tangible ideas for expanding or strengthening programs at all levels, moving beyond minimum requirements.

“These standards present new opportunities to increase alignment and strengthen collaboration between trauma centers and public health,” said NACCHO Interim Executive Director and Chief Government Affairs Officer Laura Hanen, MPP. “The care of traumatically injured patients is a public health priority and our goal is to reduce injury-related disability and death. Our collaboration with the Safe States Alliance on the standards is a step toward preventing injury before it occurs.”

Dr. Glen Tinkoff, Chair, Trauma Prevention Coalition said, “In developing the Model Level I and II Trauma Center Injury and Violence Prevention Program, the Safe States Alliance and NACCHO have provided those of us invested in hospital-based injury prevention a template of essential components to guide our programs as we seek to effectively reduce the burden of injury on the communities we serve.”

Safe States and NACCHO hosted a webinar (http://bit.ly/2jlvwsT) to share additional background on the development of the Standards and Indicators, as well as key findings. An expert panel of trauma injury and violence prevention professionals discussed its use and implications for the field.

The complete Standards and Indicators report available for all local health departments, hospital trauma centers, and partners can be accessed here.

###

About Safe States Alliance
Founded in 1993, the Safe States Alliance is a national nonprofit 501(c)(3) organization and professional association whose mission is to strengthen the practice of injury and violence prevention.

About NACCHO
The National Association of County and City Health Officials (NACCHO) represents the nation's nearly 3,000 local governmental health departments. These city, county, metropolitan, district, and tribal departments work every day to protect and promote health and well-being for all people in their communities. For more information about NACCHO, please visit www.naccho.org.

Theresa Spinner
National Association of County and City Health Officials
202-783-5551
email us here


Source: EIN Presswire

HealthLoop, Wellpepper, and Livongo Collaborate to Advance Digital Health

Three companies engaged with CMS toward inclusion of patient engagement and outcomes tracking in the MIPS Improvement Activity for provider reimbursement.

MOUNTAIN VIEW, CA, UNITED STATES, December 13, 2017 /EINPresswire.com/ — Approved digital health tools will soon be eligible for Medicare reimbursement. Beginning in 2018, physicians and other healthcare providers participating in the Merit Based Incentive Program (MIPS) track of the Medicare Access and CHIP Reauthorization Act (MACRA), can qualify for reimbursement for using clinically endorsed digital health tools to remotely guide and monitor patients outside of the clinical encounter. The new Improvement Activity recognizes the important value that digital patient engagement tools play in driving healthcare quality and lowering costs.

The new CMS MIPS Improvement Activity, entitled “Engage Patients and Families to Guide Improvement in the System of Care,” enables healthcare providers to be reimbursed for the remote monitoring, review, and interpretation of patient generated health data (PGHD) gathered through clinically endorsed mobile patient engagement applications. This provides an incentive for physicians to use digital health tools to track patient progress and improve the quality of ongoing care outside of the hospital or clinical setting while empowering patients to take more active roles in managing their own health.

Three digital health companies, HealthLoop, Wellpepper, and Livongo – leaders in this fast-growing market – collaborated in working with CMS to raise awareness of how PGHD and digital patient engagement tools can play critical roles in improving the quality of care and outcomes for patients. Top executives from the three companies also participated in the CMS PGHD Round Table in Washington, D.C. on December 6 to further the importance and understanding of the value of PGHD in patient care.

HealthLoop, Wellpepper, and Livongo can improve the level of personalized care for patients by providing ongoing guidance and assessments outside the physician-patient encounter. Physicians and care teams can use these tools to provide and adjust care plans, assist with ongoing disease management, and support return-to-work and patient quality of life improvement. Data collected from these digital health platforms can be used to track patient outcomes in support of continuous improvement initiatives and for participation in alternative payment models.

“Patient generated health data is a valuable tool in patient care,” said Anne Weiler, co-founder and CEO of Wellpepper, a clinically-validated platform for patient engagement that provides personalized, digital patient treatment plans delivered via mobile devices, SMS, email, Web and interactive voice interfaces. “We’re pleased that CMS has recognized this, and is enabling the collection and analysis to be used in demonstrating quality patient care.”

While many consumer digital devices like smart watches and activity trackers are in use by patients, the new MIPS Improvement Activity requires that physicians and other providers use clinically endorsed patient engagement and outcomes tracking tools that provide an active feedback loop – meaning they provide timely (real or near-real time) PGHD to the care team or generate timely automated feedback to the patient, such as automated patient-facing instructions based on care plan adherence or glucometer readings. These patient engagement tools may inform the patient and the clinical team of important parameters regarding a patient’s status, adherence to care plans, comprehension and indicators of clinical concern.

“This new rule is an important step forward for physicians and patients using digital engagement tools,” said Dr. Ben Rosner, CMIO of HealthLoop, a software solution that enables care teams to engage all patients before and after clinical encounters through automated daily check-ins. “For clinicians already using a patient engagement platform, these efforts will help satisfy the Improvement Activities category and earn 10 Advancing Care Information bonus points. Eligible clinicians must simply attest to completing the activity for at least 90 days to meet 2018 reporting requirements. Financial incentives aside, engaging with patients is the right thing to do. Practices using automated patient engagement solutions see reduced readmission and complication rates, lower call center volume, better online ratings for physicians, and, most important, happier, healthier patients.”

“It's not enough to want providers to expand care beyond the four walls of the office, it’s about empowering consumers and updating all parts of the system,” said Michael Sturmer, Livongo Senior Vice President of Health Services. “The new CMS MIPS Improvement Activity further connects digital health with providers and care practices and is a significant advancement in making digital health part of the fabric of the health care experience. It is better for patients and providers, and that's better for all of us.”

About HealthLoop
HealthLoop enables care teams to engage all patients before and after admission through automated daily check-ins. By sending the right information at the right time, HealthLoop identifies those patients that need help in real-time, allowing care teams to proactively intervene before costs and complications escalate. HealthLoop scales the impact of care teams through the power of patients. www.healthloop.com

About Wellpepper 
Wellpepper is a healthcare technology company with an award-winning and clinically-validated patient engagement platform used by major health systems to improve outcomes and lower costs of care. Wellpepper treatment plans can be customized for each health system’s own protocols and best practices, and personalized for each patient. Wellpepper’s patented adaptive notification system helps drive over 70% patient engagement with treatment plans. Wellpepper was founded in 2012 to help healthcare organizations lower costs, improve outcomes and improve patient satisfaction. The company is headquartered in Seattle, Washington. 

About Livongo
Livongo has a vision of empowering all people with chronic conditions to live better and healthier lives. We are redesigning chronic condition management, starting with diabetes, by driving behavior change through the combination of consumer health technology, personalized recommendations, and real-time support at the point of impact. Powered by advanced analytics, we create personalized experiences for our members so they receive the right information, tools, and support, at the right time. Our approach is leading to better financial and clinical outcomes while creating a better experience for all people with chronic conditions and their care team of family, friends, and medical professionals. www.livongo.com

Phoebe Byers
HealthLoop
4084180280
email us here


Source: EIN Presswire

Bodycad Announces EU Distribution and Consulting Agreement with OrthoGrow

Bodycad establishes critical sales channel for personalized orthopaedics with highly innovative company.

QUEBEC CITY, QUEBEC, CANADA , December 13, 2017 /EINPresswire.com/ — Bodycad has announced an exclusive agreement with OrthoGrow, a Belgian based company, for distribution and consulting services of its personalized orthopaedic knee products for the European Union.

OrthoGrow will act as Bodycad’s authorized agent for the EU in addition to establishing sales agencies in several key markets across the European Union. OrthoGrow will also assist with the marketing, promotion and training of the Bodycad portfolio.

Bodycad’s revolutionary unicompartmental knee system has optimized personalized restoration of the patient’s unique anatomical features and kinematics. The purpose-built system is based on proprietary 3D rendering of knee images, resulting in a better fit and the potential for improved clinical results and patient satisfaction

“The Bodycad knee product portfolio represents the state of the art in personalized medicine for orthopaedic applications. This is an important partnership for our future and we are pleased to be the first to commercialize this innovative technology in the European Union,” said Jeroen Dille, CEO of OrthoGrow.

Bodycad uses proprietary imaging algorithms to produce a precise 3D image of the patient’s knee. Its suite of Personalized Restoration Software enables a seamless integration of the image to implant process called the PREP (personalized restoration evaluation process). The efficient, rapid, and highly automated process is the only one of its kind in the world that is impeccably integrated between software and modern manufacturing such as 3D printing.

“OrthoGrow’s experience and leadership in innovative technologies made them a clear choice to partner with,” said Andrew McLeod, Chief Commercial Officer, for Bodycad. “We are excited to take this next step in our commercialization strategy with such a trusted partner.”

Earlier this year, the company received US and European clearance for its Unicompartmental Knee System and is working collaboratively with practitioners to offer this personalized approach to orthopaedics.

About Bodycad

Bodycad is a Quebec City-based developer and manufacturer of personalized orthopaedic restorations. They are the only company in the world to have a seamlessly integrated, purpose-built, CAD/CAM platform. Its proprietary approach offer patients a high level of conformity to their unique anatomy, with the potential for greater comfort, fit and durability that make the pursuit of orthopaedic perfection possible. Learn more at www.bodycad.com.

About OrthoGrow

OrthoGrow is a Belgium-based advisory and distribution company with a mission to help medical device companies grow and accelerate their business. OrthoGrow Advisory offers dedicated and specialized advice in Sales, Quality and Regulatory and general Business aspects for medical device manufacturers. OrthoGrow Distribution specializes in (master) distribution and authorized representative services for companies expanding their business in Europe. Learn more at www.orthogrow.com.

Andrew McLeod
Bodycad
4185271388
email us here


Source: EIN Presswire

Easton Braces Accessible & Affordable

orthodontist in Easton

Lehigh Valley orthodontist Exeter Orthodontics makes braces in Easton affordable.

Lehigh Valley orthodontist makes braces in Easton accessible and affordable for all.

We perform braces procedures all day, everyday.”

— Dr. John Pardini

EASTON, PENNSYLVANIA, UNITED STATES, December 13, 2017 /EINPresswire.com/ — Braces in Easton are now more affordable for teens and adults looking to straighten their smiles. Exeter Orthodontics in Easton offers high quality braces at one of the most affordable prices in the Lehigh Valley: only $3,995.

This low price includes emergency appointments, x-rays, adjustments, repairs, and retainers. Payment plans are also available to help Lehigh Valley families with any budget afford quality orthodontic care.

“We perform braces procedures all day, everyday,” explains Dr. John Pardini, orthodontist in Easton. “This efficiency translates into higher quality treatments at lower prices for our patients.”

In addition to braces, Invisalign® aligners are also offered in Easton for only $3,995. Invisalign aligners are a popular option for adults looking to get the benefits of braces, without the appearance of them.

With orthodontic offices in Lansdale, Reading, Center Valley, and more, Exeter Orthodontics has already helped thousands of patients across eastern Pennsylvania. Now, families across the Lehigh Valley can discover the changes a straighter smile can bring.

To learn more about braces and Invisalign aligners in Easton, request an appointment with Exeter Orthodontics: http://www.exeterorthodontics.com/request-appointment/.

About Exeter Orthodontics: For several years, Exeter Orthodontics, a Pennsylvania-based orthodontic practice, has offered area patients braces and Invisalign treatments for as low as $3,995. Its team of orthodontists remains dedicated to providing high quality care at an affordable price. Learn more at http://www.exeterorthodontics.com/.

Meredith Souder-Liss
Exeter Orthodontics
610-401-0559
email us here

Exeter Orthodontics: Affordable Braces and Invisalign Aligners in Eastern Pennsylvania


Source: EIN Presswire

Global Wheelchairs (Powered and Manual) Market 2017 Industry Analysis, Size, Share, Growth, Trends and Forecast by 2022

WiseGuyReports.com adds “Wheelchairs (Powered and Manual) Market 2017 Global Analysis, Opportunities Research Report Forecasting to 2022”reports to its database

PUNE, INDIA, December 13, 2017 /EINPresswire.com/ — Wheelchairs (Powered and Manual) Market:

Executive Summary

This report studies Wheelchairs (Powered and Manual) in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering

Invacare Corp
Sunrise Medical
Permobil Corp
Pride Mobility
Drive Medical
Handicare
Medline
Ottobock
GF Health
Karman
Hubang
Hoveround Corp
NISSIN
V. Vermeiren
MIKI
PDG

Request Sample Report @ https://www.wiseguyreports.com/sample-request/1272673-global-wheelchairs-powered-and-manual-market-professional-survey-report-2017

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Wheelchairs Powered
Wheelchairs Manual

By Application, the market can be split into

Hospitals
Recuperation mechanism
Family expenses

By Regions, this report covers (we can add the regions/countries as you want)

North America
China
Europe
Southeast Asia
Japan
India

If you have any special requirements, please let us know and we will offer you the report as you want.

For further information on this report, visit – https://www.wiseguyreports.com/enquiry/1272673-global-wheelchairs-powered-and-manual-market-professional-survey-report-2017

Table of Content:

1 Industry Overview of Wheelchairs (Powered and Manual) 
1.1 Definition and Specifications of Wheelchairs (Powered and Manual) 
1.1.1 Definition of Wheelchairs (Powered and Manual) 
1.1.2 Specifications of Wheelchairs (Powered and Manual) 
1.2 Classification of Wheelchairs (Powered and Manual) 
1.2.1 Wheelchairs Powered 
1.2.2 Wheelchairs Manual 
1.3 Applications of Wheelchairs (Powered and Manual) 
1.3.1 Hospitals 
1.3.2 Recuperation mechanism 
1.3.3 Family expenses 
1.4 Market Segment by Regions 
1.4.1 North America 
1.4.2 China 
1.4.3 Europe 
1.4.4 Southeast Asia 
1.4.5 Japan 
1.4.6 India

2 Manufacturing Cost Structure Analysis of Wheelchairs (Powered and Manual) 
2.1 Raw Material and Suppliers 
2.2 Manufacturing Cost Structure Analysis of Wheelchairs (Powered and Manual) 
2.3 Manufacturing Process Analysis of Wheelchairs (Powered and Manual) 
2.4 Industry Chain Structure of Wheelchairs (Powered and Manual)

3 Technical Data and Manufacturing Plants Analysis of Wheelchairs (Powered and Manual) 
3.1 Capacity and Commercial Production Date of Global Wheelchairs (Powered and Manual) Major Manufacturers in 2016 
3.2 Manufacturing Plants Distribution of Global Wheelchairs (Powered and Manual) Major Manufacturers in 2016 
3.3 R&D Status and Technology Source of Global Wheelchairs (Powered and Manual) Major Manufacturers in 2016 
3.4 Raw Materials Sources Analysis of Global Wheelchairs (Powered and Manual) Major Manufacturers in 2016

4 Global Wheelchairs (Powered and Manual) Overall Market Overview 
4.1 2012-2017E Overall Market Analysis 
4.2 Capacity Analysis 
4.2.1 2012-2017E Global Wheelchairs (Powered and Manual) Capacity and Growth Rate Analysis 
4.2.2 2016 Wheelchairs (Powered and Manual) Capacity Analysis (Company Segment) 
4.3 Sales Analysis 
4.3.1 2012-2017E Global Wheelchairs (Powered and Manual) Sales and Growth Rate Analysis 
4.3.2 2016 Wheelchairs (Powered and Manual) Sales Analysis (Company Segment) 
4.4 Sales Price Analysis 
4.4.1 2012-2017E Global Wheelchairs (Powered and Manual) Sales Price 
4.4.2 2016 Wheelchairs (Powered and Manual) Sales Price Analysis (Company Segment)

5 Wheelchairs (Powered and Manual) Regional Market Analysis 
5.1 North America Wheelchairs (Powered and Manual) Market Analysis 
5.1.1 North America Wheelchairs (Powered and Manual) Market Overview 
5.1.2 North America 2012-2017E Wheelchairs (Powered and Manual) Local Supply, Import, Export, Local Consumption Analysis 
5.1.3 North America 2012-2017E Wheelchairs (Powered and Manual) Sales Price Analysis 
5.1.4 North America 2016 Wheelchairs (Powered and Manual) Market Share Analysis 
5.2 China Wheelchairs (Powered and Manual) Market Analysis 
5.2.1 China Wheelchairs (Powered and Manual) Market Overview 
5.2.2 China 2012-2017E Wheelchairs (Powered and Manual) Local Supply, Import, Export, Local Consumption Analysis 
5.2.3 China 2012-2017E Wheelchairs (Powered and Manual) Sales Price Analysis 
5.2.4 China 2016 Wheelchairs (Powered and Manual) Market Share Analysis 
5.3 Europe Wheelchairs (Powered and Manual) Market Analysis 
5.3.1 Europe Wheelchairs (Powered and Manual) Market Overview 
5.3.2 Europe 2012-2017E Wheelchairs (Powered and Manual) Local Supply, Import, Export, Local Consumption Analysis 
5.3.3 Europe 2012-2017E Wheelchairs (Powered and Manual) Sales Price Analysis 
5.3.4 Europe 2016 Wheelchairs (Powered and Manual) Market Share Analysis 
5.4 Southeast Asia Wheelchairs (Powered and Manual) Market Analysis 
5.4.1 Southeast Asia Wheelchairs (Powered and Manual) Market Overview 
5.4.2 Southeast Asia 2012-2017E Wheelchairs (Powered and Manual) Local Supply, Import, Export, Local Consumption Analysis 
5.4.3 Southeast Asia 2012-2017E Wheelchairs (Powered and Manual) Sales Price Analysis 
5.4.4 Southeast Asia 2016 Wheelchairs (Powered and Manual) Market Share Analysis 
5.5 Japan Wheelchairs (Powered and Manual) Market Analysis 
5.5.1 Japan Wheelchairs (Powered and Manual) Market Overview 
5.5.2 Japan 2012-2017E Wheelchairs (Powered and Manual) Local Supply, Import, Export, Local Consumption Analysis 
5.5.3 Japan 2012-2017E Wheelchairs (Powered and Manual) Sales Price Analysis 
5.5.4 Japan 2016 Wheelchairs (Powered and Manual) Market Share Analysis 
5.6 India Wheelchairs (Powered and Manual) Market Analysis 
5.6.1 India Wheelchairs (Powered and Manual) Market Overview 
5.6.2 India 2012-2017E Wheelchairs (Powered and Manual) Local Supply, Import, Export, Local Consumption Analysis 
5.6.3 India 2012-2017E Wheelchairs (Powered and Manual) Sales Price Analysis 
5.6.4 India 2016 Wheelchairs (Powered and Manual) Market Share Analysis

6 Global 2012-2017E Wheelchairs (Powered and Manual) Segment Market Analysis (by Type) 
6.1 Global 2012-2017E Wheelchairs (Powered and Manual) Sales by Type 
6.2 Different Types of Wheelchairs (Powered and Manual) Product Interview Price Analysis 
6.3 Different Types of Wheelchairs (Powered and Manual) Product Driving Factors Analysis 
6.3.1 Wheelchairs Powered of Wheelchairs (Powered and Manual) Growth Driving Factor Analysis 
6.3.2 Wheelchairs Manual of Wheelchairs (Powered and Manual) Growth Driving Factor Analysis

7 Global 2012-2017E Wheelchairs (Powered and Manual) Segment Market Analysis (by Application) 
7.1 Global 2012-2017E Wheelchairs (Powered and Manual) Consumption by Application 
7.2 Different Application of Wheelchairs (Powered and Manual) Product Interview Price Analysis 
7.3 Different Application of Wheelchairs (Powered and Manual) Product Driving Factors Analysis 
7.3.1 Hospitals of Wheelchairs (Powered and Manual) Growth Driving Factor Analysis 
7.3.2 Recuperation mechanism of Wheelchairs (Powered and Manual) Growth Driving Factor Analysis 
7.3.3 Family expenses of Wheelchairs (Powered and Manual) Growth Driving Factor Analysis

Continuous…

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1272673

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire